These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targets of anti-influenza chemotherapy other than neuraminidase and proton pump. Shigeta S Antivir Chem Chemother; 2001; 12 Suppl 1():179-88. PubMed ID: 11594684 [TBL] [Abstract][Full Text] [Related]
4. Drugs in development for influenza. Boltz DA; Aldridge JR; Webster RG; Govorkova EA Drugs; 2010 Jul; 70(11):1349-62. PubMed ID: 20614944 [TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Antiviral Resistance in Influenza. Li TC; Chan MC; Lee N Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935 [TBL] [Abstract][Full Text] [Related]
7. Antiviral management of seasonal and pandemic influenza. Hayden FG; Pavia AT J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384 [TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitor resistance in influenza viruses. Reece PA J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169 [TBL] [Abstract][Full Text] [Related]
9. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114 [TBL] [Abstract][Full Text] [Related]
10. Inhibitors targeting the influenza virus hemagglutinin. Li F; Ma C; Wang J Curr Med Chem; 2015; 22(11):1361-82. PubMed ID: 25723505 [TBL] [Abstract][Full Text] [Related]
11. Treatment options for H5N1: lessons learned from the H1N1 pandemic. Reece PA Postgrad Med; 2010 Sep; 122(5):134-41. PubMed ID: 20861597 [TBL] [Abstract][Full Text] [Related]
13. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412 [TBL] [Abstract][Full Text] [Related]
14. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Uyeki TM Pediatr Infect Dis J; 2003 Feb; 22(2):164-77. PubMed ID: 12586981 [TBL] [Abstract][Full Text] [Related]
15. Antivirals and influenza: frequency of resistance. Monto AS Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569 [TBL] [Abstract][Full Text] [Related]
16. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery. Moorthy NS; Poongavanam V; Pratheepa V Mini Rev Med Chem; 2014; 14(10):819-30. PubMed ID: 25342196 [TBL] [Abstract][Full Text] [Related]
17. The use of antiviral agents for the management of severe influenza. Smith JR; Ariano RE; Toovey S Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416 [TBL] [Abstract][Full Text] [Related]
18. Influenza virus resistance to antiviral therapy. van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002 [TBL] [Abstract][Full Text] [Related]
19. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep; 1999 Dec; 48(RR-14):1-9. PubMed ID: 10632443 [TBL] [Abstract][Full Text] [Related]
20. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China. Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]